Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of CareSusan Olender, Jihad Slim, Àlex Soriano et al.|Clinical Infectious Diseases|2020Cited by 171
Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day MortalitySusan Olender, Marta Boffito, Theresa L. Walunas et al.|Open Forum Infectious Diseases|2021Cited by 45
Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIVRamón Teira, Juan Berenguer, Helena Díaz-Cuervo et al.|PLoS ONE|2021Cited by 10
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish CohortRamón Teira, Adrián Curran, Helena Díaz-Cuervo et al.|Infectious Diseases and Therapy|2022Cited by 6
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohortRamón Teira, Núria Espinosa, Helena Díaz-Cuervo et al.|HIV Research & Clinical Practice|2021Cited by 3